Biotech

All Articles

Pfizer takes $230M struck after axing stopped working DMD gene therapy

.Pfizer's phase 3 Duchenne muscular dystrophy (DMD) gene treatment failing has gone a $230 million g...

AC Immune observes 'site' potential in Alzheimer's medication information

.After more than two decades of deal with neurodegenerative ailments, Swiss biotech hvac Invulnerabl...

GSK falls ph. 2 HPV vaccination over shortage of best-in-class prospective

.GSK has actually broken up a period 2 individual papillomavirus (HPV) vaccine coming from its own p...

OS Treatments refiles $6M IPO to finance HER2 medicine, preclinical ADCs

.OS Therapies will certainly detail on the NYSE American stock exchange this morning using a $6.4 mi...

ALX's waning CD47 response fee sends inventory spiraling down

.ALX Oncology's period 2 stomach cancer cells response rate has weakened. After observing its own CD...

Ionis axes eye health condition coming from targets of Roche-partnered prospect after data let down

.Yet Another of Ionis Pharmaceuticals' crucial midphase readouts has fallen short of desires, causin...

Biogen's chief executive officer stated no unsafe deals in 2023. He's ready to become vibrant

.While Biogen's pharma peers are seeking for late-stage resources with little risk, chief executive ...

Instil refills pipe in $2B biobucks cope with ImmunOnco

.Instil Bio has been actually a biotech searching for a pipeline after it scrapped its lead properti...

Biogen ignores Denali Alzheimer's collab

.Biogen has actually restored rights to a very early Alzheimer's ailment plan to Denali Therapies, g...

Takeda touches new mind of US oncology company-- Chutes &amp Ladders

.Welcome to this week's Chutes &amp Ladders, our summary of substantial management hirings, firings ...